Diabetes Research Group, Helmholtz Centre Munich, Neuherberg, Germany.
Diab Vasc Dis Res. 2012 Oct;9(4):245-55. doi: 10.1177/1479164112441486. Epub 2012 Apr 16.
Diabetes is associated with an increased cardiovascular risk. The role for aspirin in diabetes is of high clinical interest. Guidelines recommend that primary prevention of cardiovascular disease (CVD) in diabetes with aspirin should be based on the individual risk for CVD. New mechanistic studies suggest that enhanced platelet turnover may partly contribute to the fact the primary prevention studies found unequivocal results in diabetes. There is initial evidence that a potential future modification of dosages in diabetes may counteract the enhancement in platelet turnover in diabetes. The use of aspirin in diabetic patients for secondary prevention of CVD is supported by key evidence. The aim of the review is to present recent studies on aspirin for prevention of CVD in diabetes and to highlight its role also in view of new mechanistic and clinical studies with aspirin. Novel aspects of aspirin, e.g. its potential role for the prevention of cancer, are also presented.
糖尿病与心血管风险增加相关。阿司匹林在糖尿病中的作用具有很高的临床意义。指南建议，糖尿病患者应用阿司匹林进行心血管疾病（CVD）一级预防应基于个体 CVD 风险。新的机制研究表明，血小板更新增强可能部分导致一级预防研究在糖尿病中得出明确结果。有初步证据表明，糖尿病中血小板更新增强可能通过潜在的未来剂量调整得到逆转。阿司匹林在糖尿病患者 CVD 二级预防中的应用得到了关键证据的支持。本综述旨在介绍近期关于阿司匹林预防糖尿病 CVD 的研究，并强调其在新的机制和临床研究中应用的作用。同时还介绍了阿司匹林的一些新方面，例如其预防癌症的潜在作用。
